Gilead Sciences Files 2023 10-K, Details Biological Products Focus

Ticker: GILD · Form: 10-K · Filed: 2024-02-23T00:00:00.000Z

Sentiment: neutral

Topics: earnings, 10-K, pharmaceuticals

Related Tickers: GILD

TL;DR

**Gilead Sciences just dropped its 2023 10-K, confirming its core biological products business.**

AI Summary

Gilead Sciences, Inc. filed its 10-K on February 23, 2024, for the fiscal year ended December 31, 2023. The filing indicates the company's continued operation as a biological products manufacturer, with its business address at 333 Lakeside Dr, Foster City, CA. The company's Central Index Key is 0000882095.

Why It Matters

This filing provides a comprehensive overview of Gilead Sciences' financial performance and operational status for 2023, crucial for investors and stakeholders to assess its stability and future prospects in the pharmaceutical industry.

Risk Assessment

Risk Level: medium — While the filing provides standard information, the pharmaceutical industry inherently carries medium risk due to R&D costs, regulatory hurdles, and patent expirations.

Key Players & Entities

FAQ

What is the Central Index Key (CIK) for GILEAD SCIENCES, INC.?

The Central Index Key (CIK) for GILEAD SCIENCES, INC. is 0000882095.

When was the 10-K filing submitted to the SEC?

The 10-K filing was submitted to the SEC on February 23, 2024.

What is the primary business classification of GILEAD SCIENCES, INC. according to the filing?

GILEAD SCIENCES, INC.'s primary business classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].

What is the fiscal year end date for the period covered by this 10-K?

The fiscal year end date for the period covered by this 10-K is December 31, 2023.

Where is GILEAD SCIENCES, INC.'s business address located?

GILEAD SCIENCES, INC.'s business address is 333 LAKESIDE DR, FOSTER CITY, CA 94404.

From the Filing

0000882095-24-000007.txt : 20240223 0000882095-24-000007.hdr.sgml : 20240223 20240223164427 ACCESSION NUMBER: 0000882095-24-000007 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 125 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240223 DATE AS OF CHANGE: 20240223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24672123 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 10-K 1 gild-20231231.htm FORM 10-K gild-20231231 0000882095 2023 FY false http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent P2M http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent P3Y P3Y 365 0000882095 2023-01-01 2023-12-31 0000882095 2023-06-30 iso4217:USD 0000882095 2024-02-16 xbrli:shares 0000882095 2023-12-31 0000882095 2022-12-31 iso4217:USD xbrli:shares 0000882095 us-gaap:ProductMember 2023-01-01 2023-12-31 0000882095 us-gaap:ProductMember 2022-01-01 2022-12-31 0000882095 us-gaap:ProductMember 2021-01-01 2021-12-31 0000882095 gild:RoyaltyContractAndOtherMember 2023-01-01 2023-12-31 0000882095 gild:RoyaltyContractAndOtherMember 2022-01-01 2022-12-31 0000882095 gild:RoyaltyContractAndOtherMember 2021-01-01 2021-12-31 0000882095 2022-01-01 2022-12-31 0000882095 2021-01-01 2021-12-31 0000882095 us-gaap:CommonStockMember 2020-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000882095 us-gaap:RetainedEarningsMember 2020-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2020-12-31 0000882095 2020-12-31 0000882095 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000882095 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000882095 us-gaap:CommonStockMember 2021-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000882095 us-gaap:RetainedEarningsMember 2021-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2021-12-31 0000882095 2021-12-31 0000882095 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000882095 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000882095 us

View on Read The Filing